Back to Careers

Juvena’s JUV-161 awarded US orphan drug designation for myotonic dystrophy type 1

Back to Careers

Juvena Therapeutics Receives FDA Orphan Drug Designation for JUV-161 for the Treatment of Myotonic Dystrophy Type 1

Back to Careers

Juvena Therapeutics is recognized in Biospace’s Top 30 list, “NextGen Class of 2024: Top Life Sciences Startups to Watch This Year”

Back to Careers

CEO Dr. Yousef speaks about “The Science of Longevity: Stopping Aging at the Cellular Level to Prevent Disease and Improve Quality of Life” as an invited panelist for the 2023 Biotech Showcase.

Back to Careers

Juvena’s CEO, Dr. Hanadie Yousef is recognized by FierceBiotech in their 2023 shortlist of 10 of the fiercest women in life sciences.

Back to Careers

Congratulations to our outstanding ML Engineer, Tejaswini Ganapathi for presenting a poster based on her AI research at Juvena entitled “Prediction of transcriptomic response to perturbagens in unobserved cell lines and cell states” at the ML Drug Discovery Symposium at Broad Institute of MIT and Harvard on October 27, 2023. We presented our exciting development of a generalized machine learning system that predicts biological effects such as gene expression changes on cells.

Back to Careers

CEO Dr. Hanadie Yousef is recognized by Business Insider on their shortlist of 30 under 40 Transforming Healthcare 

Back to Careers

The Juvena team made a big splash at the 5th Age-Related Disease Therapeutics Summit in San Francisco! CEO, Dr. Hanadie Yousef gave a well received talk on mapping secreted proteins to unmet medical needs, as well as moderating the session of impressive speakers focused on biomarkers for age-related and chronic diseases. Juvena’s VP of Data Science, Dr. Eddie Moler co-led a pre-conference workshop on exploring the promise of AI-Powered drug discovery for the progression of age-related therapies, while Computational Biologist, Dr. Rohit Jadhav presented a poster on Juvena’s proteomics platform for mining the secretomes of stem cells. 

Back to Careers

Endpoints: CEO and co-Founder Dr. Hanadie Yousef is recognized by Endpoints for her lifelong scientific work and discoveries, for her entrepreneurship and business leadership as part of the 2023 “20 under 40” list of exceptional biotech leaders and global change makers

Back to Careers

Juvena’s CEO and co-founder, Dr. Hanadie Yousef, was named among a distinguished short list of Emerging Pharma Leaders by Pharmaceutical Executive, which highlights her personal story and what drives Dr. Yousef’s passion for decoding secreted proteins for better human health